首页> 美国卫生研究院文献>Neuro-oncology Advances >NQPC-01 CURRENT STATUS AND PROBLEMS OF ADVANCE CARE PLANNING AND PALLIATIVE CARE FOR MALIGNANT BRAIN TUMOR
【2h】

NQPC-01 CURRENT STATUS AND PROBLEMS OF ADVANCE CARE PLANNING AND PALLIATIVE CARE FOR MALIGNANT BRAIN TUMOR

机译:NQPC-01恶性脑肿瘤的前期护理和姑息治疗的现状和问题

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Purpose Genomic medicine is in progress, but the median survival of glioblastoma is 14–16 months. It seems to have the same life prognosis as stage 4 like unresectable pancreatic cancer, lung cancer and colon cancer. Palliative care including Advance care planning (ACP) at first diagnosis of glioblastoma is important We conducted a questionnaire survey to understand the current status of Japanese oncologists. Method In July 2018, a questionnaire of 37 items was sent by e-mail to 767 members of Japanese Society of Neuro Oncology, and in August replies were received from 154 persons (20%). The same 22-item questionnaire in 2012–2013 was compared internationally with a report (Walbert T., et al., 2015) by Society of NeuroOncology and the European Association of NeuroOncology. In addition, we compared domestically with a 30-item questionnaire (Narita et al. 2009) in 2007. The Nonparametric Mann-Whitney’s U test was mainly used. Result 1 Characteristics of Japan in comparison with Western countries(p<0.01): 1. The number of doctors in charge is overwhelmingly male. 2. The specialty is predominantly neurosurgeons. 3. Aging of NeuroOncologists. 4, medical treatment place: the proportion of university is low. 5, frequent regular examination of the patient. Result 2Changes compared with domestic(Japan) data 11 years ago(p<0.01): 1 Explaining the condition in more detail. 2. Explaining to not only the family but also the patient. 3. Continuing chemotherapy more aggressively. 4. The place of death: decreasing at hospitals and increasing at home. 5, Frequency with a respirator decreased. 6, About 70% at the end of the period, nasal injection and gastrostomy are applied. Conclusion In the treatment of malignant brain tumors in Japan, a male neurosurgeon who has over 15 years of experience actively continues chemotherapy and appears to see it with nasal injection.
机译:目的基因组医学正在开发中,但胶质母细胞瘤的中位生存期为14-16个月。与不可切除的胰腺癌,肺癌和结肠癌一样,它的预后与第4期相同。胶质母细胞瘤的首次诊断中包括姑息治疗计划(ACP)在内的姑息治疗很重要我们进行了问卷调查,以了解日本肿瘤科医生的当前状况。方法2018年7月,通过电子邮件向日本神经肿瘤学会的767名成员发送了37项问卷调查表,并在8月收到154人的答复(占20%)。 2012年至2013年,同一项22项问卷在国际上与神经肿瘤学会和欧洲神经肿瘤协会的一份报告(Walbert T.等,2015)进行了国际比较。此外,我们在2007年与30项问卷(Narita等,2009)进行了国内比较。主要使用非参数曼惠特尼(Mann-Whitney)的U检验。结果1日本与西方国家相比的特征(p <0.01):1.主管医生中绝大多数是男性。 2.专长是神经外科医生。 3.神经肿瘤学家的衰老。 4,就医场所:大学比例低。 5,经常定期检查病人。结果2与11年前国内(日本)数据相比的变化(p <0.01):1更详细地说明情况。 2.不仅向家人解释,而且向患者解释。 3.更积极地继续化疗。 4.死亡地点:在医院减少而在家里增加。 5,用呼吸器的频率降低。 6,期末约有70%的患者采用鼻腔注射和胃造口术。结论在日本的恶性脑肿瘤治疗中,具有15年以上经验的男性神经外科医生积极地继续化疗,并且似乎通过鼻腔注射看到了它。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号